First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive

Study to Investigate Safety of TissuGlu and its Effect on Wound Drainage and Associated Complications in Abdominoplasty (Tummy Tuck) Surgeries

PITTSBURGH, December 16 - Cohera Medical Inc. today announced the treatment of the first patient in
a study of its lead surgical adhesive product, TissuGlu(R). Initiation of the
study marks a major milestone in the company's progression of the lead
product toward clinical practice.

The clinical investigation is a prospective, open-label, randomized study
to investigate the safety of TissuGlu and its effect on wound drainage and
associated complications in abdominoplasty, or "tummy tuck," surgeries. The
study will compare standard wound closure techniques to standard wound
closure techniques plus the application of TissuGlu in 40 patients at three
sites near Bonn, Frankfurt and Freiburg, Germany.

"We are delighted to have treated the first patient in the TissuGlu
study," said Klaus Walgenbach, M.D., Ph.D., of the Universitatsklinikum Bonn
and the principal investigator for the study. "We were very pleased with the
procedure and look forward to enrolling more patients."

Currently, patients who undergo abdominoplasty require the insertion of
drains to remove fluids that accumulate under the skin at the surgical site.
In some cases, drainage is inadequate, and the excess fluid accumulation
called seroma requires an additional procedure for removal. TissuGlu adheres
the tissue flaps created during the procedure to reduce fluid accumulation,
and, ultimately, the duration of use of the surgical drains. With the use of
TissuGlu, patients may experience a significant reduction of fluid
accumulation and a more comfortable recovery, which may lead to a quicker
return to normal activity.

"Our transition into the clinical development phase brings us closer to
helping plastic surgeons to address a critical unmet need and improve patient
care," said Patrick Daly, president and chief executive officer of Cohera
Medical. "Furthermore, the market opportunity for our company with TissuGlu
is very significant, ranging between US$500 million and US$750 million from
2011 to 2015. If you add the additional applications such as facelift, breast
reconstruction and body contouring that we will pursue with TissuGlu, the
opportunity increases to between US$700 million to more than US$1 billion
over the same five-year period."

Chad Coberly, J.D., vice president of clinical, regulatory and legal
affairs of Cohera Medical, added: "Initiation of this study culminates
significant preclinical work by our company and investigators and
demonstrates the primary safety profile of this product. This study will
enable us to move closer to CE Mark application in Europe and will provide
important data in application for a larger U.S.-based trial in 2010."

Preclinical data published in the July 2008 issue of Plastic and
Reconstructive Surgery show that TissuGlu prevented seroma formation in an
animal abdominoplasty model. Summarized in a paper titled "Lysine-Derived
Urethane Surgical Adhesive Prevents Seroma Formation in a Canine
Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1:
95-102) the results demonstrated that TissuGlu successfully prevented the
formation of seroma in a novel large-animal model designed to evaluate seroma
formation. While the control side in all seven animals used in the study
demonstrated large, clinically significant seromas, the side treated with
TissuGlu showed little or no evidence of fluid accumulation. In addition,
histologic analysis of tissue samples from the animals showed no signs of
inflammation or foreign body reaction associated with the adhesive.

"The progress with the development of TissuGlu represents a significant
next step in the value creation for Cohera Medical's investors," said Doros
Platika, M.D., the company's chairman. "Most importantly, it signifies a
potential major advance for surgical patients that may help to decrease
complications and improve clinical outcomes."

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a
revolutionary line of surgical adhesives. Cohera Medical's products are based
on a unique chemical design that is purely synthetic, easy to use,
biocompatible and fully resorbable. The company's lead product in
development, TissuGlu, is an adhesive for plastic surgery procedures.
TissuGlu adheres flaps of tissue after surgical procedures, eliminating the
spaces where fluid accumulates and reducing wound drainage. Cohera Medical is
also developing surgical adhesives targeting mesh fixation, small bone
fixation and other plastic surgery indications that will fill similar market
needs in plastic, orthopedics and general surgery. For more information,
visit www.coheramed.com. TissuGlu and the other Cohera products are currently
indicated for investigational use only and have not yet been approved for
medical use by the Food and Drug Administration (FDA) in the U.S. or in any
other market.

Certain statements made throughout this news release that are not
historical facts contain forward-looking statements regarding the Company's
future plans, objectives and expected performance. Any such forward-looking
statements are based on assumptions that the Company believes are reasonable,
but are subject to a wide range of risks and uncertainties and, therefore,
there can be no assurance that actual results may not differ materially from
those expressed or implied by such forward-looking statements.

David Schull, david.schull at russopartnersllc.com or Martina Schwarzkopf, Ph.D., martina.schwarzkopf at russopartnersllc.com, both of Russo Partners, +1-212-845-4271; Patrick Daly, Cohera Medical, +1-412-231-1500, ext. 101, pdaly at coheramed.com; Clinical Trial Contact: Chad Coberly, Cohera Medical, +1-412-246-2563, ccoberly at coheramed.com